Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium

Abstract

When 22 members of the BrainNet Europe (BNE) consortium assessed 31 cases with a-synuclein (aS) immunoreactive (IR) pathology applying the consensus protocol described by McKeith and colleagues in 2005, the inter-observer agreement was 80%, being lowest in the limbic category (73%). When applying the staging protocol described by Braak and colleagues in 2003, agreement was only 65%, and in some cases as low as 36%. When modifications of these strategies, i.e., McKeith's protocol by Leverenz and colleagues from 2009, Braak's staging by Müller and colleagues from 2005 were applied then the agreement increased to 78 and 82%, respectively. In both of these modifications, a reduced number of anatomical regions/blocks are assessed and still in a substantial number of cases, the inter-observer agreement differed significantly. Over 80% agreement in both typing and staging of aS pathology could be achieved when applying a new protocol, jointly designed by the BNE consortium. The BNE-protocol assessing aS-IR lesions in nine blocks 123Acta Neuropathol (2009) 117:635-652 DOI 10.1007 offered advantages over the previous modified protocols because the agreement between the 22 observers was over 80% in most cases. Furthermore, in the BNE-protocol, the aS pathology is assessed as being present or absent and thus the quality of staining and the assessment of the severity of aS-IR pathology do not alter the inter-observer agreement, contrary to other assessment strategies. To reach these high agreement rates an entity of amygdalapredominant category was incorporated. In conclusion, here we report a protocol for assessing aS pathology that can achieve a high inter-observer agreement for both the assignment to brainstem, limbic, neocortical and amygdala-predominant categories of synucleinopathy and the Braak stages.

Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson’s Disease

“…Full individual demographic data can be found in supplementary Table 1. Preliminary experiments showed that the post-mortem interval did not affect the signal of PAR2 in brain ( Supplementary Fig 1). The clinical diagnosis of Parkinson's disease was confirmed post-mortem by neuropathological analysis and the degree of α-synuclein was rated and each case was allocated an α-synuclein Braak stage (Alafuzoff et al, 2009;Braak et al, 2003). Control cases had no clinical diagnosis of a neurological or psychiatric disorder during life, nor any neuropathological abnormality evident post-mortem.…”

The role of α-synuclein in neurodegeneration — An update

“…Both cortical and subcortical AS pathologies have been suggested to be the main determinant [693,694], whereas others suggested AD pathology to be more important, particularly when the Aβ load may be similar to that in AD [695]. The severity and extent of AS are variable, and according to revised guidelines are scored semiquantitatively in specific brain areas [593,[696][697][698][699]. AD pathology is a consistent but not universal finding in both disorders, differentiating two types of DLB: The "common form" is characterized by abundant neocortical senile plaques and NFTs in the limbic cortex; while "pure DLB" shows minimal AD lesions [700].…”

New Insight in The Molecular Mechanisms of Neurodegenerative Disease

“…When the most severe stages of the progression are reached, these altered proteins were considered to be causative of NDDs such as AD, PD, DLB, FTLD-TDP and ALS. (27)(28)(29)(30)(31)(32)(33) Recently, a new entity, primary age-related tauopathy (PART), which describes neurologically unimpaired aged subjects with HPt pathology in the hippocampus, has been defined. (34) It has even been debated whether subjects with PART represent an early stage of AD or merely reflect a neurodegenerative process at an early stage.…”